Dimethyl Sulfoxide Case: Objective Comparison & Brand Recommendation of Well-Known Chinese Manufacturers

HiSiaddi is an innovative foreign trade service provider driven by dual engines of technology transformation and foreign trade services. It has established a service system framed as "1+2+3+4=1" and can supply DMSO sourced from multiple well-known original manufacturers.

As a foreign trade enterprise with R&D capabilities, HiSiaddi has repeatedly conducted multi-round factory inspections of DMSO manufacturers and developed in-depth objective insights into different brands. Accordingly, we regularly analyze various DMSO manufacturers for clients to help them select suitable products. Below is a brand recommendation case.

For more brand and model comparison analysis, please contact HiSiaddi customer service.

I. Client Basic Information (Premium European Fine Chemical End User, Not Intermediary or Low-End Manufacturer)

Aurora Chem, a listed fine chemical manufacturer headquartered in Geneva, Switzerland, specializes in high-end cosmetic actives and targeted pharmaceutical intermediates, distributing products across the EU and North America. All production lines comply with EP Pharmacopoeia, REACH, GMP and COA full control standards. DMSO is deployed in two core processes: low-temperature extraction of plant active ingredients and crystallization of pharmaceutical small molecules, with stable annual procurement of 72 tons. The client requires low mercaptan odor, low heavy metal content and consistent batch-to-batch stability. It previously sourced DMSO exclusively from the U.S.-based Gaylord, and planned domestic substitution amid rising overseas raw material prices and extended lead times, yet lacked familiarity with mainstream domestic DMSO brands and sub-models.

The client independently contacted five leading domestic manufacturers: Xingfa, Jincheng Pharmaceutical, Luxi, Xinhua Co., Ltd. and Haixiang. All manufacturers provided objectively compliant sales materials without malicious competitor defamation, yet intentionally omitted peer advantages while overemphasizing their own strengths: Xingfa highlighted bulk industrial-grade advantages while avoiding purification shortcomings for pharmaceutical use; Jincheng only emphasized pharmacopoeia qualifications without disclosing mass production cost drawbacks; Luxi prioritized spot inventory while concealing upper limits for ultra-high-purity specifications. The client received five biased product data sheets with mixed parameters and confusing model classifications, making horizontal comparison impossible. Small-batch trial applications in extraction processes yielded unstable extraction yields and excessive active ingredient impurities, delaying final brand selection. The client entrusted HiSiaddi Foreign Trade to deliver neutral full-brand evaluations and model screening.

II. Comprehensive Review of Five Leading Domestic DMSO Manufacturers & Core Models (Neutral Research by HiSiaddi)

Drawing on years of fine chemical supply chain databases and on-site factory visit data, HiSiaddi delivers an objective breakdown of product positioning, core models, strengths, weaknesses and applicable scenarios for the five brands, free from supply interest bias, for submission to the Swiss client:

1. Hubei Xingfa Group (Domestic Capacity Leader, Full Product Portfolio)

· Core Models: Industrial Premium Grade DMSO (HX-998), Primary Purified Pharmaceutical Grade (HX-M1)

· Advantages: Largest annual DMSO production capacity in the industry, self-sourced raw materials for low costs, abundant spot inventory, stable large-batch consistency, standard water content ≤0.08%, complete supporting packaging solutions. Suitable for large-volume conventional extraction and pesticide synthesis;

· Drawbacks: Limited high-end pharmacopoeia-grade purification production lines. HX-M1 heavy metal control ranges from 3–5ppm, failing to meet EU pharmaceutical intermediate strict standard of <1ppm. Trace sulfide odor exceeds dedicated purification brands, rendering it unsuitable for highly sensitive pharmaceutical crystallization processes.

2. Shandong Jincheng Pharmaceutical (Domestic Benchmark for Pharmaceutical-Grade DMSO)

· Core Models: Pharmacopoeia High-Purity DMSO (JC-EP9999, EP/USP Pharmacopoeia Grade), Cell Cryopreservation Special Grade JC-Cryo

· Advantages: One of few domestic manufacturers holding FDA-DMF and EU CEP certifications. Four-stage negative pressure rectification process delivers JC-EP9999 purity ≥99.995%, heavy metals <0.8ppb, endotoxin <0.001EU/mL, fully matching specifications of imported European and American raw materials. Ideal for pharmaceutical crystallization and cell-related manufacturing;

· Drawbacks: Restricted high-end purification production capacity, extended scheduling lead times for large-volume orders, unit prices 12%–18% higher than Xingfa and Luxi for equivalent specifications, low cost-effectiveness for mass raw material extraction.

3. Shandong Luxi Chemical (Established Coal Chemical Conglomerate)

· Core Models: National Standard First-Grade LX-999 (99.9%), Purified Modified LX-PH

· Advantages: Large on-site warehousing capacity, rapid nationwide nearby delivery, stable standard impurity control for LX-999, desulfurized modified LX-PH with low odor, suitable for mid-tier cosmetic raw material extraction, low minimum order thresholds for small batches;

· Drawbacks: No EP Pharmacopoeia certification, unable to issue EU-recognized pharmacopoeia compliance documents, limited ultra-high-purity customization capacity, failing to meet strict regulatory entry requirements for pharmaceutical intermediates in Switzerland.

4. Zhejiang Xinhua Co., Ltd. (Dual Layout of Electronics & Fine Chemicals)

· Core Models: Electronic Grade DX-G3, Fine Pharmaceutical Intermediate DX-MED

· Advantages: Membrane separation + precision rectification process, DX-G3 achieves ppb-level metal ion control, DX-MED optimized for solvent compatibility in organic synthesis with stable low-temperature solidification indicators, dual applicability for electronic cleaning and fine synthesis;

· Drawbacks: Small-scale pharmaceutical mass production, limited spot inventory for DX-MED, unstable lead times for emergency replenishment orders.

5. Jiangsu Haixiang Chemical (Leading Bulk Export Manufacturer)

· Core Models: Export National Standard Grade HX-OUT998, Custom Purified HX-FINE

· Advantages: Long-term export experience to Southeast Asia and the Middle East, mature hazardous goods export customs clearance support, outstanding cost performance for general grades;

· Drawbacks: High-end pharmaceutical-grade models lack EU CEP and DMF filings, with documentation failing to satisfy Swiss Customs pharmaceutical raw material entry audits.

III. Two Preferred Brands & Three Deployable Models Selected Based on Client Production Requirements

Considering the client’s two separate production lines (cosmetic plant extraction + pharmaceutical intermediate crystallization), Xingfa and Haixiang were eliminated due to regulatory/impurity non-compliance, and Xinhua was excluded due to unstable spot supply. Two mid-to-high-end manufacturers – Shandong Jincheng Pharmaceutical and Shandong Luxi Chemical – were shortlisted with three precision-matched models deployed across different workflows:

Preferred Brand 1: Shandong Jincheng Pharmaceutical (For Pharmaceutical Intermediate Crystallization Workflow)

1. Model JC-EP9999 (EP Pharmacopoeia High-Purity Grade): Exclusively deployed for targeted drug crystallization, fully compliant with EP Pharmacopoeia specifications with qualified heavy metals, endotoxin and trace sulfides, serving as a direct replacement for original U.S. Gaylord imported DMSO;

2. Model JC-Cryo reserved for small-batch trial samples for future new cell therapy project R&D.

Preferred Brand 2: Shandong Luxi Chemical (For Cosmetic Plant Active Ingredient Extraction Workflow)

1. Model LX-PH Modified Desulfurized Purified Grade: Optimized for plant extraction with low odor and water content ≤0.03%, meeting cosmetic active extraction requirements while drastically cutting raw material procurement costs versus Jincheng’s ultra-high-purity grade.

Selection Logic: Differentiated raw material allocation across two production lines – benchmark pharmacopoeia brand for high-end crystallization and cost-effective purified grade for mid-tier extraction – balancing quality compliance and production costs, a combined solution unavailable from single manufacturers.

IV. Implementation Execution Steps

1. HiSiaddi coordinated three parallel sample batches from both manufacturers, unified full-indicator testing by SGS per EU standards, and supported client on-site production line small trials;

2. Small trial results: JC-EP9999 delivered equivalent crystallization yields to original U.S. imported DMSO; LX-PH increased plant extraction recovery by 2.3% with no residual odor;

3. Assist the client in splitting the annual 72-ton order: 41 tons of Jincheng JC-EP9999 and 31 tons of Luxi LX-PH, shipped in six monthly batches;

4. One-Stop Supporting Services: Unified processing of REACH documentation, English COA, hazardous goods export customs clearance documents and customized 20L pharmaceutical packaging, eliminating communication overhead from separate engagement with two manufacturers.

V. Cooperation Outcomes

1. Procurement Implementation: The client formally signed an annual framework procurement contract for stable supply of the two selected models, reducing overall raw material procurement costs by 31% versus original U.S. imported sources and completing successful domestic substitution;

2. Long-Term Binding Partnership: The client entrusted HiSiaddi with additional DMSO model screening for subsequent transdermal skincare formulation R&D;

3. Demonstrated Differentiated Advantages of HiSiaddi: Distinct from manufacturer sales teams that only promote their own products, HiSiaddi delivers neutral third-party cross-brand evaluations, enabling high-end overseas clients to break free from single-brand limitations and implement scenario-split targeted model selection, establishing HiSiaddi as the client’s exclusive solvent selection consultant in China.

VI. Case Summary

The core selection pain point for high-end overseas clients is not insufficient supply access, but manufacturer brand bias preventing objective horizontal comparison and evaluation. HiSiaddi eliminates supply interest conflicts to neutrally analyze brand strengths and weaknesses and design split-scenario formulation solutions, representing the core competitive edge distinguishing high-end fine chemical foreign trade from generic spot goods resale.

For more brand and model comparison analysis, please contact HiSiaddi customer service.